Our overarching goal is to push innovation in acute lymphoblastic leukemia (ALL) drug discovery by establishing a microfluidic impedance platform, which accommodates 3D microtissues and circulating cancer cells, and which will, in the long term, enable to develop treatments of many forms of ALL. At the end of the project, we aim at having a reliable in-vitro screening platform prototype and process, which then can be modified for use with other cell-circulation-based diseases.